Síndrome de hiper-IgM: Lesiones mucocutáneas y neutropenia

Revista Alergia Mexico

Volumn 49, Issue 2, 2002, Pages 57-59

  Escarcega Barbosa D ^a   Ortiz Jimenez M P ^a   Juarez Garcia J ^a   Miranda Feria, A J ^a  

^a CENTRO MÉDICO NACIONAL 20 DE NOVIEMBRE   (Mexico)

Author keywords

Hyper IgM syndrome mucocutaneous ulcerations; Neutropenia

Indexed keywords

IMMUNOGLOBULIN M;

ARTICLE; CASE REPORT; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; HUMAN; HYPERGAMMAGLOBULINEMIA; ISOLATION AND PURIFICATION; MALE; NEUTROPENIA; PATHOLOGY; PRESCHOOL CHILD; SKIN ULCER;

CHILD, PRESCHOOL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; HUMANS; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN M; MALE; NEUTROPENIA; SKIN ULCER;

EID: 84866592917     PISSN: 00025151     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Rosen FS, Kevy SV, Merler E, Janeway CA, Gitlin D. Recurrent bacterial infections and dysgammaglobulinemia: deficiency of 7S gamma-globulins in the presence of elevated 19S gamma-globulins: report of two cases. Pediatrics 1961;28:18295.
2. Rosen FS, Cooper MD, Wedgwood RJ. The primary immunodeficiencies. N Engl J Med 1995;333:431-40.
3. Allen RC, Armitage RJ, Conley ME, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993;259:990-3.
4. Hollenbaugh D, Grosmaire LS, Kullas CD, Chalupny NJ, Braesch-Andersen S, Noelle RJ, et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J 1992;11:4313-21.
5. Nonoyama S, Hollenbaugh D, Aruffo A, Ledbetter JA, Ochs HD. B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells. J Exp Med 1993;178:1097-102.
6. Durie FH, Foy TM, Masters SR, Laman JD, Noelle RJ. The role of CD40 in the regulation of humoral and cell mediated immunity. Immunol Today 1994;15:406-11.
7. Notarangelo LID, Peitsch MC. CD40Lbase: a database of CD40L gene mutations causing X-linked hyper-IgM syndrome. Immunol Today 1996;17:511-6.
8. Cunningham CK, Bonville CA, Ochs HD, et al. Enteroviral meningoencephalitis as a complication of X-linked hyper-IgM syndrome. J Pediatr 1999;134:584-8.
9. Levy J, Español-Boren T, Thomas C, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 1997;131:47-54.
10. Iseki M, Anzo M, Yamashita N, Matsuo N. Hyper-IgM immunodeficiency with disseminated cryptococcosis. Acta Paediatr 1994;8:780-2.
11. Subauste CS, Wessendarp M, Sorensen RU, Leiva LE. CD40-CD40 ligand interaction is central to cell-mediated immunity against Toxoplasma gondii. Patients with hyper-IgM syndrome have a defective type 1 immune response that can be restored by soluble CD40 ligand trimmer. J Immunol.
12. Abrahamsen TG, et al. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics 1996;98:1127-31.
13. Thomas C, de Saint Basile G, Le Deist F, et al. Correction of X-linked hyper-IgM syndrome by allogeneic bone marrow transplantation. N Engl J Med 1995;333:426-9.
14. Chang WM, Romero R, Scholl RP, Paller AS. Mucocutaneous manifestations of the hyper-IgM immunodeficiency syndrome. J Am Acad Dermatol 1998;38:191-6.
15. Lacroix-Demazes S, Resnick I, Stahl D, Mouthon L, Espanol T, et al. Defective self-reactive antibody repertoire of serum IgM in patients with hyper-IgM syndrome. J Immunol 1999;162:5601-8.